British researchers say this drug could revolutionize the treatment of multiple sclerosis.
Cladribine is already licensed for treating leukemia. It works by suppressing the immune system, reducing the risk of further damage to a patient's nervous system.
The study was presented at the American Academy of Neurology meeting.
The company that makes cladribine hopes to seek licensing for use this year.